# Lifetech CeraFlex™ Post-Market Surveillance Study

Study · id `cardio:ct-nct02621528` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02621528](<https://clinicaltrials.gov/study/NCT02621528>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02621528

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT02621528. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (actual); primary completion 2019-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT02621528, source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)
- Started: 2015-10 (actual) (ClinicalTrials.gov record NCT02621528, source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)
- Primary completion: 2019-01 (actual) (ClinicalTrials.gov record NCT02621528, source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)
- Completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02621528, source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)
- Countries: France; Germany; Ireland; Italy; Switzerland (ClinicalTrials.gov record NCT02621528, source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02621528-2020-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Lifetech CeraFlex™ Post-Market Surveillance Study
- Condition: Patent Foramen Ovale
- Condition: Atrial Septal Defect
- Condition: Patent Ductus Arteriosus
- Intervention (Device): CeraFlex
- Lead sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. (`cardio:org-lifetech-scientific-shenzhen-co-ltd`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: ad8611730ad16c6fc945f49a13912fadfdbfc9b6230cbdd08a1f5ce494028a8a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
